UNSTRUCTURED
With the advent of immune checkpoint inhibitors (ICIs) for cancer treatment, patients use online forums to share experiences. As many as 60% of patients taking ICIs will develop cutaneous immune-related adverse events, which can be a good prognostic indicator for ICI treatment response. This paper explores patient sentiments in online reviews on drugs.com to ICIs, pembrolizumab and nivolumab, using Python with Selenium and manual review. There were statistically significant higher mean overall patient ratings in reviews mentioning dermatologic symptoms (DS) compared to those that did not (mean of 5.7/10 vs. 4.0/10, P=.007), and a trend towards higher sentiment scores as well (P=.074). Finally, DS-containing reviews more frequently reported positive cancer outcomes (P<.001).